Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis
Dates
study started
completion around

Description

Summary

This phase II trial studies how well giving azacitidine and entinostat work in treating patients with advanced breast cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving azacitidine together with entinostat may kill more tumor cells.

Official Title

Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer

Details

Keywords

Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma, Carcinoma, Breast Neoplasms, Male Breast Neoplasms, Azacitidine, Entinostat, Histone Deacetylase Inhibitors, Laboratory Biomarker Analysis, Pharmacological Study

Eligibility

Locations

  • University of California Davis Comprehensive Cancer Center
    Sacramento California 95817 United States
  • USC / Norris Comprehensive Cancer Center
    Los Angeles California 90033 United States
  • City of Hope Comprehensive Cancer Center
    Duarte California 91010 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT01349959
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 58 people participating
Last Updated